GSK and CureVac to develop vaccines to tackle Covid variants
Published
The €150m investment is to address various coronavirus strains in one jab
Full ArticlePublished
The €150m investment is to address various coronavirus strains in one jab
Full ArticleDrugs giant GlaxoSmithKline and German biotech firm CureVac have struck a €150m (£130m) deal to develop next-generation COVID-19..